ARWR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Arrowhead Pharmaceuticals Inc (ARWR) presents a mixed investment opportunity for a beginner investor with a long-term focus. While the company has promising developments in its obesity pipeline and strong analyst support, the recent financial performance, lack of immediate trading signals, and neutral trading sentiment suggest it is not an optimal buy at the current moment. A hold recommendation is advised until further catalysts or financial improvements materialize.
The MACD histogram is positive at 0.432, suggesting a bullish momentum. RSI is at 69.264, indicating a neutral zone with no overbought or oversold conditions. Moving averages are converging, showing no clear trend direction. Key support is at 54.735, and resistance is at 61.447, with the stock price currently near resistance levels.
Strong analyst support with multiple Buy ratings and price targets ranging from $80 to $
Promising obesity pipeline with Phase 3 readouts expected in Q3
Significant YoY revenue growth of 10461.32% in Q1 2026.
Net income and EPS have dropped significantly YoY, indicating profitability challenges.
No recent congress trading data or influential figure activity.
Neutral sentiment from hedge funds and insiders, with no significant trading trends.
In Q1 2026, revenue increased significantly by 10461.32% YoY to $264.03M, but net income dropped by -117.80% YoY to $30.81M, and EPS fell by -115.83% YoY to 0.22. Gross margin remains strong at 100%.
Analysts remain optimistic, with several Buy ratings and price targets raised to as high as $101. However, some analysts express caution due to mixed competitor data and questions about the obesity pipeline's valuation. The consensus is that Arrowhead's long-term value proposition is strong, but near-term catalysts are limited.
